BioSpace News Archive

Sumitovant Biopharma Ltd. (“Sumitovant”) and Myovant Sciences Ltd. (“Myovant”) announced today that Sumitovant has successfully completed its acquisition of Myovant originally announced October 23, 2022.

Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) (“Satellos” or the “Company”), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, is pleased to announce additional results from further preclinical studies using the Company’s lead drug candidate SAT-3153.

Orchard Therapeutics, a global gene therapy leader, announced that the Company’s previously disclosed change to its American Depositary Share to ordinary share ratio has been made effective.

Canadians across the country have named LifeLabs’ as the Most Trusted Brand in Health Diagnostic Services.

ACG, a leading supplier of integrated manufacturing solutions to the global pharmaceutical and nutraceutical industries, is pleased to announce that Richard Stedman will be re-joining the business as the Group CEO of the Engineering division.

Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it is expanding its U.S. presence and establishing a corporate presence on the West Coast with new offices in South San Francisco, California and Seattle, Washington.

New research in the March 2023 issue of JNCCN—Journal of the National Comprehensive Cancer Network highlights how the lack of genomic research for people with African ancestry, particularly those from the Sub-Saharan region, is hampering efforts to reduce disparities for people with cancer.

Fulcrum Therapeutics, Inc.® announced that the Company granted non-statutory stock options to new employees.

Science 37 Holdings, Inc., the industry-leading Metasite™, announced the granting of inducement equity awards under the Science 37 Holdings, Inc. 2022 Employment Inducement Incentive Award Plan.

Acadia Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration has approved DAYBUE™ for the treatment of Rett syndrome in adult and pediatric patients two years of age and older.